Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DKY709 · 1 trial · 5 indications
Incidence and severity of AEs and SAEs
The incidence of DLTs during the first cycle of treatment with single agent DKY709 or the combination of DKY709 with PDR001.
Incidence and severity of AEs and SAEs
| Arm | Type | Description |
|---|---|---|
| DKY709 | EXPERIMENTAL | DKY709 monotherapy |
| DKY709 + PDR001 | EXPERIMENTAL | Combination therapy with DKY709 and PDR001 |
| Name | Type | Description |
|---|---|---|
| DKY709 | DRUG | Novel immunomodulatory agent |
| PDR001 | DRUG | PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2 |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Patients must be ≥18 years of age at the time of informed consent form (ICF) signature. 3. Patients with advanced/metastatic cancer who have progressed despite having received standard therapy in...
DKY709 is an investigational small molecule being studied for the treatment of advanced solid tumors, including carcinoma, non-small-cell lung cancer, melanoma, nasopharyngeal carcinoma, microsatellite stable colorectal cancer, and triple negative breast cancer. It is currently in Phase 1 clinical development.
DKY709 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its potential anti-tumor activity in advanced solid tumors, both as a single agent and in combination with PDR001.
DKY709 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
DKY709 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with advanced solid tumors.
DKY709 is being studied in a Phase 1 clinical trial with the identifier NCT03891953. This trial evaluates the safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors, including non-small-cell lung cancer, melanoma, and other cancers.
No, DKY709 is not the same as PDR001. DKY709 is an investigational small molecule being studied as a single agent and in combination with PDR001, which is a separate investigational drug. The combination is being evaluated in a Phase 1 clinical trial for advanced solid tumors.